Single and Multiple Dose Pharmacokinetics, Pharmacodynamics and Safety of the Novel Lipoprotein-Associated Phospholipase A(2) Enzyme Inhibitor Darapladib in Healthy Chinese Subjects: An Open Label Phase-1 Clinical Trial

BACKGROUND AND OBJECTIVES: Darapladib is a lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) inhibitor. This study evaluated the pharmacokinetics, pharmacodynamics and safety of darapladib in healthy Chinese subjects. METHODS: Twenty-four subjects received darapladib 160 mg orally, approximately...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Chaoying, Tompson, Debra, Magee, Mindy, Chen, Qian, Liu, Yan Mei, Zhu, Wenjing, Zhao, Hongxin, Gross, Annette S., Liu, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605839/
https://www.ncbi.nlm.nih.gov/pubmed/26465780
http://dx.doi.org/10.1371/journal.pone.0139862

Ejemplares similares

Ejemplares similares